Trials / Suspended
SuspendedNCT03752541
Efficacy and Safety Evaluation of BCMA-UCART
Efficacy and Safety Evaluation of BCMA-UCART（Allogeneic Engineered T-cells Expressing Anti-BCMA Chimeric Antigen Receptor）in the Treatment of Relapsed or Refractory Multiple Myeloma
- Status
- Suspended
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Bioray Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with relapsed or refractory multiple myeloma.
Detailed description
BCMA(B-Cell maturation antigen) is a tumor antigen of multiple myeloma. Using a genetic engineering strategy to assemble an anti-BCMA CAR(chimeric antigen receptor) in T cells will help these CART cells to recognize and kill BCMA-expressing MM tumor cells. BCMA-UCART is a kind of allogeneic CART, originating from T cells of health donors. This open-label, dose-escalation study aims to evaluate the safety and anti-tumor efficacy of BCMA-UCART in treating relapsed or refractory multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BCMA-UCART | A conditioning therapy with cyclophosphamide and fludarabine will be conducted for subjects before CART therapy. |
Timeline
- Start date
- 2019-11-01
- Primary completion
- 2023-03-20
- Completion
- 2023-11-20
- First posted
- 2018-11-26
- Last updated
- 2022-05-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03752541. Inclusion in this directory is not an endorsement.